Genprex Reports $4.46 Million Net Loss in Q1 2026, Highlights Increased R&D Expenses

Genprex, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $4.46 million, an increase of 13% from the $3.96 million loss recorded in the same period of 2025. The company's operating expenses rose to $4.49 million, up from $3.97 million year-over-year, primarily driven by increased research and development (R&D) costs associated with ongoing clinical trials and general administrative expenses. R&D expenses totaled $2.75 million, reflecting an 8% increase from $2.54 million in the prior year, while general and administrative expenses surged by 22% to $1.75 million, attributed to higher corporate franchise taxes and professional service costs.

In terms of liquidity, Genprex reported cash and cash equivalents of $18.05 million as of March 31, 2026, a significant increase from $7.83 million at the end of 2025. This boost in cash was largely due to financing activities, where the company raised approximately $13.36 million through the sale of 5.71 million shares of common stock under its at-the-market (ATM) offering program. The company also noted a decrease in cash used in operating activities, which fell to $3.14 million from $4.16 million in the previous year, indicating improved cash management.

Strategically, Genprex is advancing its clinical programs, particularly the Acclaim-1 and Acclaim-3 trials, which are focused on its lead oncology product, REQORSA® Gene Therapy. The Acclaim-1 trial is currently in the Phase 2a expansion stage, while the Acclaim-3 trial is also enrolling patients. The company has received Fast Track Designation from the FDA for both trials, which is expected to expedite the development process. Additionally, Genprex has entered into a new sponsored research agreement with the University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient responses to REQORSA.

The company continues to face challenges, including the need for additional capital to fund its operations and clinical trials. Genprex has indicated that it expects to require further financing to support its ongoing development efforts, particularly as it aims to complete the interim enrollment of the Phase 2a expansion portion of the Acclaim-1 trial and the Phase 2 expansion of the Acclaim-3 trial in the first half of 2026. The company has expressed uncertainty regarding its ability to maintain liquidity and continue as a going concern, emphasizing the importance of securing additional funding to sustain its operations and development initiatives.